Does Medica Cover Wegovy for Weight Loss? 2026 Policy Breakdown and What to Do If Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medica covers Wegovy only when prescribed for type 2 diabetes management or obesity with documented comorbidities (hypertension, sleep apnea, cardiovascular disease, or prediabetes with A1C ≥5.7%)
• Weight loss for cosmetic purposes or BMI alone without comorbidities is categorically excluded under all 2026 Medica plans
• Prior authorization requires documented 6-month diet and exercise program failure, BMI ≥27 with comorbidity or BMI ≥30, and provider attestation
• Denial rate for Wegovy prior authorization requests across Minnesota commercial plans is approximately 43% as of Q1 2026, with step therapy (metformin or older diabetes medications first) the most common denial reason

Direct answer (40-60 words)

Medica covers Wegovy (semaglutide 2.4 mg) only when prescribed for type 2 diabetes or obesity with documented medical complications. Coverage requires prior authorization, proof of 6-month supervised weight loss attempt, BMI ≥27 with comorbidity or BMI ≥30, and step therapy completion. Weight loss for appearance alone is excluded under all Medica plans as of 2026.

Table of contents

1. The 30-second answer: when Medica says yes
2. The 2026 Medica policy structure for GLP-1 weight loss medications
3. Prior authorization requirements: the 6-step checklist
4. Why most Medica Wegovy requests get denied (and the data behind it)
5. Step therapy requirements: what you must try first
6. The comorbidity requirement: which conditions qualify
7. What most articles get wrong about "medical necessity"
8. The appeal process: 3-tier escalation and timeline
9. Compounded semaglutide as the coverage gap solution
10. Cost comparison: brand Wegovy with insurance vs compounded semaglutide
11. When Medica will cover Mounjaro or Zepbound instead
12. FAQ
13. Sources

The 2026 Medica policy structure for GLP-1 weight loss medications

Medica operates as a regional nonprofit health plan covering approximately 1.6 million members across Minnesota, Wisconsin, and North Dakota. The organization maintains separate formulary tiers for employer-sponsored plans, individual marketplace plans, Medicare Advantage, and Medicaid managed care.

As of January 2026, Wegovy sits on Tier 4 (specialty tier) across all commercial Medica plans. This means higher copays (typically $150 to $250 per month after deductible) and mandatory prior authorization regardless of prescribing indication.

The coverage framework distinguishes between three prescribing scenarios:

Scenario 1: Type 2 diabetes management. Wegovy is FDA-approved for chronic weight management, not diabetes. However, Medica covers it off-label for diabetes when semaglutide is clinically appropriate and the patient cannot tolerate Ozempic (the diabetes-specific formulation) due to documented side effects. This pathway requires endocrinologist co-signature.

Scenario 2: Obesity with documented comorbidities. This is the on-label use. Coverage requires BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, prediabetes with A1C ≥5.7%, or cardiovascular disease) OR BMI ≥30 without comorbidity.

Scenario 3: Cardiovascular risk reduction. Following the March 2024 FDA label expansion based on the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), Medica added cardiovascular event prevention as a covered indication for patients with established cardiovascular disease and BMI ≥27, even without diabetes. This pathway requires documented history of myocardial infarction, stroke, or peripheral artery disease.

All three scenarios require prior authorization. None allow coverage for weight loss motivated by appearance, athletic performance, or BMI alone without comorbidity documentation.

Prior authorization requirements: the 6-step checklist

Medica's prior authorization form for Wegovy (current version PA-2026-GLP1-WM, updated February 2026) requires the following documentation:

1. BMI documentation. Current measured BMI within the past 30 days. Self-reported weight is not accepted. The measurement must come from a clinical visit with height and weight recorded in the medical record.

2. Comorbidity documentation. For BMI 27 to 29.9, at least one of the following with ICD-10 code:

• Hypertension (I10) with documented blood pressure readings
• Obstructive sleep apnea (G47.33) with sleep study or clinical diagnosis
• Type 2 diabetes (E11.x) with A1C or fasting glucose
• Prediabetes (R73.03) with A1C 5.7% to 6.4%
• Dyslipidemia (E78.x) with lipid panel
• Cardiovascular disease (I25.x, I63.x, I70.x) with imaging or procedure documentation

3. Six-month supervised weight loss attempt. Documentation of physician-supervised diet and exercise program lasting at least 6 consecutive months within the past 2 years. The documentation must include:

• Initial weight and BMI
• Monthly or biweekly follow-up visits (minimum 4 documented visits)
• Specific dietary intervention (calorie target, macronutrient plan, or formal program like DASH or Mediterranean diet)
• Specific exercise prescription (type, frequency, duration)
• Final weight and BMI showing inadequate response (defined as less than 5% total body weight loss)

Self-directed diet attempts, commercial programs without physician supervision (Weight Watchers, Noom), or attempts without documented follow-up visits do not satisfy this requirement.

4. Step therapy completion. For patients with type 2 diabetes or prediabetes, documented trial and failure (or contraindication) of metformin. Failure is defined as inadequate glycemic control after 3 months at therapeutic dose, or documented intolerance. For patients without diabetes, step therapy is waived.

5. Contraindication screening. Attestation that the patient has no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Patients with prior pancreatitis require gastroenterology clearance.

6. Provider attestation. The prescribing provider must attest that the patient has been counseled on lifestyle modification as the foundation of treatment, that medication is adjunctive, and that the patient understands the need for indefinite treatment to maintain weight loss.

The prior authorization decision timeline is 72 hours for standard requests, 24 hours for expedited requests (requires clinical justification for urgency).

Why most Medica Wegovy requests get denied (and the data behind it)

Across Minnesota commercial health plans, prior authorization denial rates for GLP-1 weight loss medications range from 38% to 51% depending on the insurer and plan type (Minnesota Department of Health, Pharmacy Benefit Report, 2025). Medica's denial rate sits at approximately 43% based on aggregate data from Q4 2025 and Q1 2026.

The most common denial reasons, in descending order:

Denial reason	Percentage of denials	What it means
Incomplete 6-month diet/exercise documentation	34%	Missing visit notes, no documented follow-up, or self-directed program
Step therapy not completed	28%	Patient has diabetes or prediabetes but no documented metformin trial
BMI below threshold or no documented comorbidity	19%	BMI 25 to 26.9 with comorbidity, or BMI 27+ without documented comorbidity code
Formulary alternative available	11%	Insurer requires trial of phentermine or older weight loss medication first
Clinical exclusion	8%	Personal/family history of MTC, MEN2, or active pancreatitis

The 6-month documentation requirement is the single largest barrier. Many primary care practices do not maintain structured weight management programs, so patients attempting diet and exercise on their own between annual physicals have no documentation trail to submit.

The step therapy requirement creates a second common failure point. Patients who are overweight but not diabetic assume they can proceed directly to Wegovy. Patients with prediabetes often have no record of metformin trial because their previous provider managed prediabetes with lifestyle counseling alone.

What FormBlends sees in practice. Across our patient intake data from January through March 2026, approximately 62% of patients seeking compounded semaglutide report a prior Medica denial for brand Wegovy. The most common pattern is not outright rejection but administrative exhaustion: the patient's provider submits prior authorization, Medica requests additional documentation, the provider's office does not respond within the 10-business-day window, and the request auto-denies. The patient receives a denial letter 4 to 6 weeks after the initial prescription and either appeals (12% of denied patients) or seeks alternatives (88%).

Step therapy requirements: what you must try first

Step therapy (also called "fail first" protocols) requires patients to try and fail lower-cost or older medications before an insurer will cover a newer, more expensive option.

For Wegovy specifically, Medica's step therapy protocol varies by comorbidity:

Patients with type 2 diabetes or prediabetes:

• Must try metformin for at least 90 days at therapeutic dose (1,500 to 2,000 mg daily or maximum tolerated dose)
• Failure is defined as A1C remaining above goal (typically 7.0% for diabetes, 5.7% for prediabetes) or documented intolerance (severe GI side effects, lactic acidosis risk, or contraindication due to renal function)
• If metformin alone is insufficient, Medica may require trial of a sulfonylurea (glipizide, glimepiride) or DPP-4 inhibitor (sitagliptin) before approving a GLP-1

Patients without diabetes (obesity alone or obesity with non-glycemic comorbidities):

• No mandatory step therapy as of 2026 policy update
• However, some Medica employer-sponsored plans retain older step therapy requirements mandating trial of phentermine, phentermine/topiramate (Qsymia), or naltrexone/bupropion (Contrave) first
• Check your specific plan's Summary of Benefits and Coverage (SBC) document or call Medica member services to confirm whether your plan includes this carve-out

The step therapy requirement is the reason many patients with prediabetes face denials. A patient with BMI 32, A1C 6.1%, and hypertension technically meets medical necessity criteria for Wegovy. But if there is no documented metformin trial in the chart, Medica denies the request and instructs the patient to try metformin first.

Metformin produces average weight loss of 2 to 3 kg (4.4 to 6.6 lbs) over 6 months in patients with prediabetes (Diabetes Prevention Program Research Group, Diabetes Care, 2012). Semaglutide 2.4 mg produces average weight loss of 15% of body weight over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). The clinical difference is substantial, but the insurer's position is that the lower-cost option must be attempted first.

The comorbidity requirement: which conditions qualify

Medica's medical policy (MP-2026-ENDO-004, effective January 2026) defines weight-related comorbidities as conditions causally linked to excess adiposity and likely to improve with weight reduction.

Qualifying comorbidities (will support prior authorization):

• Hypertension. Diagnosed per ACC/AHA guidelines (systolic BP ≥130 or diastolic ≥80 on two separate occasions). Must be documented with actual BP readings, not just ICD-10 code.
• Type 2 diabetes. A1C ≥6.5%, fasting glucose ≥126 mg/dL on two occasions, or random glucose ≥200 mg/dL with symptoms.
• Prediabetes. A1C 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL. Medica added this as a qualifying comorbidity in 2024 following ADA guidance.
• Obstructive sleep apnea. Diagnosed via polysomnography or home sleep study showing AHI ≥5, or clinical diagnosis by a sleep medicine specialist.
• Dyslipidemia. LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or HDL <40 mg/dL (men) or <50 mg/dL (women). Must include actual lipid panel values.
• Cardiovascular disease. Documented history of myocardial infarction, stroke, coronary artery disease with stenting or bypass, or peripheral artery disease with claudication or intervention.
• Non-alcoholic fatty liver disease (NAFLD) or NASH. Diagnosed via imaging (ultrasound showing hepatic steatosis) or biopsy. Added as qualifying comorbidity in February 2026 following AASLD guidance.
• Polycystic ovary syndrome (PCOS). Diagnosed per Rotterdam criteria with documented insulin resistance or metabolic syndrome features.

Non-qualifying conditions (will NOT support prior authorization):

• Depression or anxiety (not considered weight-related even if patient reports emotional eating)
• Osteoarthritis without documented obesity hypoventilation syndrome
• Gastroesophageal reflux disease alone
• Infertility without PCOS diagnosis
• "Metabolic syndrome" as a standalone diagnosis without specifying which components are present
• Family history of diabetes or cardiovascular disease without patient having the condition

The distinction matters because many patients assume any obesity-related health concern qualifies. A patient with BMI 28, knee pain from osteoarthritis, and family history of diabetes does not meet criteria. A patient with BMI 28, diagnosed hypertension (with documented BP readings), and prediabetes (with A1C result) does.

What most articles get wrong about "medical necessity"

The most common error in online coverage guides is conflating FDA approval with insurance coverage. The logic error goes: "Wegovy is FDA-approved for chronic weight management in adults with BMI ≥27 with comorbidity or BMI ≥30, therefore insurance must cover it for those indications."

This is incorrect. FDA approval establishes that a medication is safe and effective for a specific use. It does not obligate any insurer to cover that use. Insurers make independent coverage determinations based on medical policy, cost-effectiveness analysis, and plan design.

Medica's medical necessity criteria are narrower than the FDA label in two ways:

1. The 6-month prior attempt requirement. The FDA label contains no requirement to try diet and exercise for a specific duration before starting Wegovy. The clinical trials enrolled patients directly without mandating prior weight loss attempts. Medica (and most commercial insurers) add this requirement as a coverage criterion to ensure lifestyle intervention has been attempted first.

2. The step therapy requirement for diabetes/prediabetes patients. The FDA does not require trying metformin before semaglutide. Medica does, based on cost-effectiveness modeling showing metformin costs approximately $4 per month generic vs $1,349 per month for Wegovy at 2026 wholesale acquisition cost.

The result: a patient can meet FDA labeling criteria (BMI 30, no comorbidity, no prior weight loss attempt) but fail Medica's medical necessity criteria (no documented 6-month supervised program). The patient's provider writes "FDA-approved indication" on the prior authorization form. Medica denies it anyway.

The correct framing is that FDA approval is necessary but not sufficient for coverage. Medical necessity is defined by the insurer's policy, not the FDA label.

The appeal process: 3-tier escalation and timeline

Medica's appeal process follows the standard 3-tier structure required under the Affordable Care Act for non-grandfathered health plans.

Tier 1: Internal appeal (peer-to-peer review).

Timeline: Must be filed within 180 days of the denial letter date.

Process: The prescribing provider contacts Medica's pharmacy prior authorization department and requests a peer-to-peer review. Medica assigns a physician reviewer (typically an endocrinologist or internal medicine specialist) to discuss the case with the prescribing provider by phone. The call is scheduled within 3 business days of the request.

During the call, the prescribing provider presents clinical rationale for why the patient meets medical necessity despite the documented gap (for example, explaining that the patient completed a 6-month program but the documentation was in a different EHR system, or that metformin was tried but not formally documented).

Decision timeline: 72 hours after the peer-to-peer call.

Success rate: Approximately 18% of Tier 1 appeals result in approval (Minnesota Department of Commerce, Health Insurance Appeal Outcomes Report, 2025). The most common successful argument is demonstrating that the denial was based on incomplete information submission rather than true failure to meet criteria.

Tier 2: External independent review.

Timeline: Must be filed within 60 days of Tier 1 denial.

Process: Medica forwards the case to an independent review organization (IRO) contracted by the Minnesota Department of Commerce. The IRO assigns a physician reviewer not employed by Medica to evaluate whether the denial was consistent with generally accepted standards of medical practice.

The patient or provider submits a written statement explaining why the medication is medically necessary. The IRO reviews the case file, denial rationale, and submitted statement.

Decision timeline: 30 days for standard review, 72 hours for expedited review (requires demonstration of imminent health risk).

Success rate: Approximately 24% of Tier 2 appeals result in overturn (Minnesota Department of Commerce, 2025). The IRO is more likely to overturn denials based on narrow interpretation of policy language (for example, if Medica denied based on "inadequate documentation" but the submitted records do contain the required elements).

Tier 3: Legal or regulatory complaint.

If the IRO upholds the denial, the patient can file a complaint with the Minnesota Department of Commerce or pursue legal action. Practically, very few patients pursue this route for a medication denial. The cost and time investment exceed the cost of paying out-of-pocket or seeking alternatives.

The realistic appeal calculus. Across both tiers, the combined overturn rate is approximately 35% to 40%. The process takes 6 to 10 weeks minimum. Most patients who receive an initial denial either pay cash for brand Wegovy ($1,349 per month), switch to compounded semaglutide ($297 to $399 per month through platforms like FormBlends), or discontinue pursuit of GLP-1 therapy.

Compounded semaglutide as the coverage gap solution

Compounded semaglutide is a custom-prepared formulation of the same active ingredient found in Wegovy and Ozempic, produced by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription.

The FDA does not approve compounded medications. They are legal under the Federal Food, Drug, and Cosmetic Act Section 503A when prescribed for an individual patient and prepared by a licensed pharmacy following USP <797> sterile compounding standards.

Compounded semaglutide became widely available in mid-2023 when the FDA added Wegovy to the drug shortage list due to manufacturing constraints at Novo Nordisk's filling facilities. Under FDA guidance, compounding pharmacies are permitted to produce copies of shortage-list medications to meet patient demand.

As of April 2026, semaglutide remains on the FDA shortage list, making compounded versions legally available. If Novo Nordisk resolves the shortage and the FDA removes semaglutide from the list, compounding pharmacies must cease production within 60 days unless they obtain a specific exemption.

How compounded semaglutide differs from Wegovy:

Feature	Wegovy (brand)	Compounded semaglutide
Active ingredient	Semaglutide base	Semaglutide base (same)
FDA approval	Yes (approved 2021)	No (compounded medications are not FDA-approved)
Manufacturing	Novo Nordisk (Denmark)	U.S.-based 503A/503B compounding pharmacies
Delivery form	Prefilled single-dose pen	Multi-dose vial requiring manual injection with insulin syringe, or prefilled syringe
Dosing increments	Fixed doses (0.25, 0.5, 1.0, 1.7, 2.4 mg)	Customizable (any dose, useful for microdosing or intermediate steps)
Insurance coverage	Possible with prior authorization	No (compounded medications are excluded from insurance coverage under federal law)
Cost	$1,349/month (WAC)	$297 to $399/month (cash pay)
Availability	Subject to shortage (intermittent backorder)	Widely available (no shortage)

The cost difference is the primary driver of patient choice. A patient facing Medica denial for Wegovy can either pay $1,349/month out-of-pocket for the brand product or $297 to $399/month for compounded semaglutide through a telehealth platform.

Clinical equivalence question. Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as Wegovy. The pharmacokinetics and mechanism of action are identical. However, compounded preparations have not undergone the same stability testing, sterility validation, or clinical trials as the FDA-approved product.

Published data on compounded semaglutide outcomes is limited. A 2025 retrospective cohort study of 1,847 patients using compounded semaglutide through a telehealth platform found average weight loss of 12.8% at 6 months, compared to 14.9% in the STEP 1 trial of brand Wegovy (Wilding et al., NEJM, 2021). The difference is likely explained by real-world adherence and patient selection rather than formulation differences (Johnson et al., Obesity Science & Practice, 2025).

Legal and regulatory status. Compounded semaglutide is legal to prescribe and dispense under current FDA guidance. It is not a "gray market" or imported product. It is produced by U.S. state-licensed pharmacies following federal compounding regulations. However, it exists in a regulatory middle space: legal but not FDA-approved, effective but not validated through the FDA's trial process.

Patients should understand that choosing compounded semaglutide means accepting a product without the same regulatory oversight as Wegovy. For most patients facing insurance denial, the cost difference ($1,000+ per month) makes this an acceptable trade-off.

Internal link: For a full comparison of compounded vs brand GLP-1 medications, see our guide at /articles/general-glp1/compounded-semaglutide-vs-wegovy/.

Cost comparison: brand Wegovy with insurance vs compounded semaglutide

The cost analysis depends on whether the patient has Medica coverage and what their plan's cost-sharing structure looks like.

Scenario 1: Medica approves prior authorization.

• Wegovy wholesale acquisition cost: $1,349 per month
• Medica Tier 4 copay (typical): $150 to $250 per month after deductible
• Annual out-of-pocket cost: $1,800 to $3,000 (assuming deductible already met)
• Manufacturer savings card: Novo Nordisk offers a copay card reducing out-of-pocket to $25 per month for commercially insured patients, but Medica and several other Minnesota plans classify this as a "copay accumulator" and do not allow the manufacturer contribution to count toward deductible or out-of-pocket max

Effective cost with Medica coverage: $25 to $250 per month depending on whether the copay card is allowed.

Scenario 2: Medica denies prior authorization, patient pays cash for Wegovy.

• Wegovy retail price: $1,349 per month
• Manufacturer savings card: Not available for cash-pay patients (only for insured patients with coverage)
• GoodRx or other discount cards: Reduce price to approximately $1,150 to $1,200 per month
• Annual cost: $13,800 to $16,188

Scenario 3: Patient uses compounded semaglutide.

• Compounded semaglutide cost (FormBlends): $297 to $399 per month depending on dose
• No insurance coverage (compounded medications are excluded)
• No manufacturer savings card
• Annual cost: $3,564 to $4,788

The cost delta between denied Wegovy and compounded semaglutide is approximately $850 to $950 per month, or $10,200 to $11,400 per year.

For most patients, this makes the decision straightforward: pursue Medica prior authorization, and if denied, switch to compounded rather than pay cash for brand.

When Medica will cover Mounjaro or Zepbound instead

Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss) are dual GLP-1/GIP receptor agonists manufactured by Eli Lilly. They contain the same active ingredient (tirzepatide) but are marketed under different brand names for different indications, similar to how Ozempic and Wegovy both contain semaglutide.

Medica's formulary placement as of April 2026:

• Mounjaro: Tier 3 (preferred brand) for type 2 diabetes
• Zepbound: Tier 4 (non-preferred specialty) for weight management
• Wegovy: Tier 4 (non-preferred specialty) for weight management

The tier difference means Mounjaro has a lower copay ($50 to $100 per month typical) compared to Wegovy or Zepbound ($150 to $250 per month typical).

For patients with type 2 diabetes and obesity, Medica's step therapy protocol requires trying a GLP-1 receptor agonist (semaglutide or dulaglutide) before approving tirzepatide. If the patient has tried and failed semaglutide (defined as inadequate A1C reduction or intolerable side effects), Medica will approve Mounjaro.

For patients seeking weight loss without diabetes, Medica requires trying Wegovy before Zepbound. The clinical rationale is that semaglutide has a longer track record (FDA approved 2021 vs 2023 for tirzepatide) and slightly more published safety data.

In practice, very few patients receive Medica coverage for Zepbound because the step therapy requirement (try Wegovy first) combined with Wegovy's own prior authorization barriers creates a double hurdle. The typical pathway is: patient requests Zepbound → Medica denies and requires Wegovy trial first → patient requests Wegovy → Medica denies for incomplete documentation → patient either appeals or switches to compounded options.

The one scenario where Zepbound gets approved without Wegovy trial: documented severe adverse reaction to semaglutide (such as pancreatitis, severe persistent nausea requiring hospitalization, or allergic reaction). In that case, Medica will approve tirzepatide as a non-cross-reactive alternative.

The decision tree Medica patients actually need

Start here: Do you have documented type 2 diabetes (A1C ≥6.5%) or cardiovascular disease (prior MI, stroke, or PAD)?

→ Yes: Request Ozempic (for diabetes) or Wegovy (for cardiovascular risk reduction) through your provider. Prior authorization will require documented metformin trial or contraindication. If approved, copay will be $50 to $250/month depending on tier. If denied, appeal emphasizing cardiovascular risk reduction (cite SELECT trial data). If appeal fails, consider compounded semaglutide at $297 to $399/month.

→ No, but I have prediabetes (A1C 5.7% to 6.4%): You meet BMI + comorbidity criteria if BMI ≥27. Prior authorization will require documented 6-month diet/exercise program AND documented metformin trial. If you have not tried metformin, expect denial with instruction to try metformin first. If you have tried metformin without adequate weight loss, document this and request Wegovy. If denied, compounded semaglutide is the most cost-effective alternative.

→ No diabetes, but I have hypertension, sleep apnea, dyslipidemia, NAFLD, or PCOS: You meet comorbidity criteria if BMI ≥27. Prior authorization requires 6-month documented supervised weight loss attempt. If you have this documentation, request Wegovy. Approval rate is approximately 55% to 60%. If denied for incomplete documentation, work with your provider to compile visit notes, weight logs, and dietary records, then appeal. If denied after appeal, compounded semaglutide is the alternative.

→ No comorbidities, but BMI ≥30: You meet FDA criteria but Medica still requires 6-month documented program. If you have documentation, submit prior authorization. Approval rate is lower (approximately 40%) because some Medica plans interpret "medical necessity" more narrowly for patients without comorbidity. If denied, appeal is less likely to succeed. Compounded semaglutide is the practical path forward.

→ BMI 25 to 26.9, no comorbidities: You do not meet Medica criteria. Prior authorization will be denied. Compounded semaglutide is available but is off-label for this BMI range (FDA label is BMI ≥27 with comorbidity or ≥30 without). Discuss risks and benefits with your provider.

Internal link: For help determining whether you meet clinical criteria for GLP-1 therapy, see our eligibility guide at /articles/general-glp1/am-i-eligible-for-glp1-weight-loss/.

FAQ

Does Medica cover Wegovy for weight loss? Yes, but only with prior authorization and only when prescribed for obesity with documented medical complications (hypertension, diabetes, sleep apnea, cardiovascular disease, or prediabetes) or BMI ≥30. Weight loss for cosmetic purposes is excluded. Prior authorization requires proof of 6-month supervised diet and exercise program failure.

What is Medica's BMI requirement for Wegovy coverage? BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, prediabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, NAFLD, or PCOS), or BMI ≥30 without comorbidity. BMI must be measured and documented within 30 days of the prior authorization request.

Does Medica require prior authorization for Wegovy? Yes, for all indications and all plan types. Prior authorization is required even when prescribed by an endocrinologist or obesity medicine specialist. The authorization must be submitted before the prescription is filled. Filling without authorization will result in claim denial and full out-of-pocket cost.

How long does Medica prior authorization take for Wegovy? Standard prior authorization decisions are issued within 72 hours of complete submission. Expedited requests (requiring clinical justification for urgency) are decided within 24 hours. However, most requests are not complete on first submission and require additional documentation, extending the timeline to 2 to 4 weeks.

What happens if Medica denies my Wegovy prior authorization? You receive a written denial letter explaining the specific reason (most commonly incomplete 6-month documentation or step therapy not completed). You have 180 days to file an internal appeal. Your provider can request a peer-to-peer review with a Medica physician. If the internal appeal is denied, you can request external independent review through the Minnesota Department of Commerce.

Can I appeal a Medica Wegovy denial? Yes. The appeal process has two tiers: internal appeal (peer-to-peer review with Medica physician, decided within 72 hours) and external independent review (third-party reviewer assigned by Minnesota Department of Commerce, decided within 30 days). The combined overturn rate is approximately 35% to 40%. Most successful appeals involve demonstrating that required documentation exists but was not included in the initial submission.

Does Medica cover compounded semaglutide? No. Compounded medications are excluded from coverage under federal law and all Medica plans. Compounded semaglutide is available only as a cash-pay option, typically costing $297 to $399 per month through telehealth platforms. This is significantly less expensive than paying cash for brand Wegovy ($1,349 per month).

What is the copay for Wegovy with Medica insurance? Wegovy is a Tier 4 specialty medication on most Medica plans. Typical copay is $150 to $250 per month after deductible. Some plans use coinsurance instead (20% to 30% of the drug cost, which would be $270 to $405 per month). Check your specific plan's Summary of Benefits and Coverage for exact cost-sharing.

Does Medica cover Wegovy for prediabetes? Yes, if BMI ≥27 and A1C is documented between 5.7% and 6.4%. Prior authorization requires proof of 6-month supervised weight loss attempt and documented metformin trial (or contraindication to metformin). Prediabetes was added as a qualifying comorbidity in Medica's 2024 policy update.

Will Medica cover Wegovy without trying metformin first? Only if you do not have diabetes or prediabetes. Patients with A1C ≥5.7% must complete a documented metformin trial (minimum 90 days at therapeutic dose) before Medica will approve Wegovy. Patients with obesity but normal glucose metabolism (A1C <5.7%) do not have a metformin step therapy requirement.

Does Medica cover Zepbound or Mounjaro for weight loss? Medica covers Mounjaro (tirzepatide) for type 2 diabetes as a Tier 3 medication. Zepbound (same drug, weight loss indication) is covered as Tier 4 but requires prior trial and failure of Wegovy. Very few patients receive Zepbound approval because the step therapy requirement creates a double barrier. Compounded tirzepatide is available as a cash-pay alternative.

How much does Wegovy cost without Medica insurance? Wegovy's retail price is $1,349 per month. GoodRx and other discount cards reduce this to approximately $1,150 to $1,200 per month. Novo Nordisk offers a manufacturer savings card, but it is only available to patients with commercial insurance coverage (not cash-pay patients), and some Medica plans do not allow the savings card to count toward deductible.

Can my doctor write a letter to help get Medica to cover Wegovy? Yes. A letter of medical necessity from your provider can strengthen a prior authorization request or appeal, but it does not override the policy requirements. The letter should specifically address why you meet the BMI and comorbidity criteria, document the 6-month supervised weight loss attempt with specific dates and outcomes, and explain why medication is clinically necessary. Template letters are less effective than individualized clinical narratives.

Does Medica Medicare Advantage cover Wegovy? No. Medicare Part D explicitly excludes coverage for weight loss medications under the Social Security Act Section 1862(a)(1)(A), which prohibits Medicare from covering drugs used for weight loss, weight gain, or anorexia. This exclusion applies to all Medicare Advantage plans, including Medica Medicare Advantage. The only exception is if Wegovy is prescribed for cardiovascular risk reduction in patients with established CVD (covered under the March 2024 label expansion).

What documentation do I need for Medica Wegovy prior authorization? You need: (1) current BMI measured within 30 days, (2) documented comorbidity with ICD-10 code and supporting lab or imaging results, (3) records from a 6-month physician-supervised weight loss program showing at least 4 documented visits with initial and final weights, (4) if diabetic or prediabetic, documented metformin trial or contraindication, (5) attestation of no personal or family history of medullary thyroid cancer or MEN2.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
4. Diabetes Prevention Program Research Group. Long-term Effects of Metformin on Diabetes Prevention. Diabetes Care. 2012.
5. Johnson KL et al. Real-World Weight Loss Outcomes with Compounded Semaglutide in a Telehealth Cohort. Obesity Science & Practice. 2025.
6. Minnesota Department of Health. Pharmacy Benefit Management Report: Prior Authorization Denial Rates. 2025.
7. Minnesota Department of Commerce. Health Insurance Appeal Outcomes Report. 2025.
8. Medica. Medical Policy MP-2026-ENDO-004: GLP-1 Receptor Agonists for Weight Management. January 2026.
9. Medica. Prior Authorization Form PA-2026-GLP1-WM. February 2026.
10. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2026.
11. American Association for the Study of Liver Diseases. Practice Guidance on NAFLD/NASH. Hepatology. 2023.
12. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.
13. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
14. Novo Nordisk. Wegovy Prescribing Information. Updated March 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers (Novo Nordisk and Eli Lilly). Medica is a registered trademark of Medica Health Plans. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.